Evommune Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	48.32	44.06	16.26	29.02
Short-Term Investments	163.15	105.14	55.79	50.06
Cash & Short-Term Investments	211.46	149.2	72.04	79.08
Cash Growth	336.78%	107.11%	-8.91%	-
Other Current Assets	4.39	4.28	1.95	0.95
Total Current Assets	215.86	153.48	73.99	80.03
Net Property, Plant & Equipment	9.57	2.46	1.8	1.97
Long-Term Investments	95.55	67.49	-	-
Other Long-Term Assets	1.48	1.52	0.27	0.25
Total Assets	322.46	224.95	76.06	82.25
Accounts Payable	4.05	7.76	8.26	1.76
Accrued Expenses	4.73	9.55	6.73	4.03
Current Portion of Leases	1.25	0.24	0.49	0.77
Unearned Revenue	-	-	3	-
Other Current Liabilities	0.57	0.36	9.5	0.3
Total Current Liabilities	10.6	17.91	27.98	6.86
Long-Term Leases	6.77	1.29	-	0.49
Other Long-Term Liabilities	0.53	0.18	0.54	3.25
Total Long-Term Liabilities	7.3	1.47	0.54	3.73
Total Liabilities	17.9	19.38	28.52	10.59
Common Stock	0	0	-	-
Additional Paid-in Capital	547.31	426.65	7.98	6.2
Retained Earnings	-242.76	-221.09	-152.22	-83.91
Total Common Shareholders' Equity	304.56	205.57	-144.24	-77.71
Minority Interest	-	-	191.78	149.37
Shareholders' Equity	304.56	205.57	47.54	71.66
Total Liabilities & Equity	322.46	224.95	76.06	82.25
Total Debt	8.02	1.53	0.49	1.26
Net Cash (Debt)	203.44	147.67	71.55	77.83
Net Cash Growth	37.77%	106.38%	-8.06%	-
Net Cash Per Share	14.39	24.06	47.44	62.10
Book Value	304.56	205.57	-144.24	-77.71
Book Value Per Share	21.55	33.50	-95.63	-62.01
Tangible Book Value	304.56	205.57	-144.24	-77.71
Tangible Book Value Per Share	21.55	33.50	-95.63	-62.01

SEC Filings: 10-K · 10-Q